Sign in with Google. Opens in new tab

Shanghai Junshi Bioscience (1877.HK/688180.CH) - Behind the “break Up” with AstraZeneca

395 Views10 Jan 2022 01:05
The insight analyzed Junshi in terms of the potential reasons behind the termination of PD-1 commercialization partnership with AstraZeneca, the outlook, the change of FDA attitude and other concerns.
SUMMARY
(Sign Up to Access)
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
chart-bar
x